T1	Participants 94 162	younger patients with nonacute promyelocytic acute myeloid leukemia:
T2	Participants 194 260	genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
T3	Participants 334 457	chemotherapy for younger patients with nonacute promyelocytic acute myeloid leukemia and high-risk myelodysplastic syndrome
T4	Participants 537 576	1075 patients less than 60 years of age
